Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL)

Neven, P.Fasching, P. A.Chia, S.Jerusalem, G.De laurentiis, M.Im, S. -A.Petrakova, K.Bianchi, G. V.Martin Jimenez, M.Nusch, A.Sonke, G. S.de la Cruz Merino, L.Beck, J. T.Zarate, J. P.Wang, Y.Chakravartty, A.Wang, C.Slamon, D.2023-05-032023-05-032022-05-050923-7534http://hdl.handle.net/10668/21910enUpdated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL)conference outputopen access10.1016/j.annonc.2022.03.2801569-8041http://www.annalsofoncology.org/article/S092375342200758X/pdf792494100163